This review highlights the significant advances made in the diagnosis and management of penile cancer.
This often-aggressive tumor phenotype has been characterized by its poor prognosis, mostly attributable to its late presentation and heterogeneity of surgical care because of the paucity of cases treated at most centers. Recent advances in understanding of the risk factors predisposing to penile cancer, including its association with the human papilloma virus (HPV), have brought forth the socioepidemiologic concept of HPV vaccination in certain high-risk populations and countries, which remains highly debated. The management of penile cancer has evolved in recent years with the adoption of penile-sparing and minimally invasive surgical approaches to the inguinal lymph nodes, which are a frequent site of regional spread for this malignancy. Lastly, this review highlights the importance of adopting a multimodal approach consisting of neoadjuvant systemic chemotherapy followed by consolidative surgical resection in patients presenting with bulky/locally advanced nodal metastases from penile cancer.
Written by:
Spiess PE, Horenblas S, Pagliaro LC, Biagioli MC, Crook J, Clark PE, Greenberg RE, Ercole CE. Are you the author?
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Division of Brachytherapy, Moffitt Cancer Center, Tampa, Florida; University of British Columbia, BCCA Center for the Southern Interior, British Columbia, Canada; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee; and Department of Urology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Reference: J Natl Compr Canc Netw. 2013 May 1;11(5):617-624.
PubMed Abstract
PMID: 23667210
UroToday.com Penile and Urethral Cancers Section
